ABBV vs COP: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and ConocoPhillips — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
ConocoPhillips · Energy
$125.78
-2.1% upside to fair value
Grade C
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
COP trades at a lower forward P/E
(21.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
COP |
| Current Price |
$197.69 |
$125.78 |
| Fair Value Estimate |
$210.22 |
$123.15 |
| Upside to Fair Value |
+6.3%
|
-2.1%
|
| Market Cap |
$349.7B |
$153.3B |
| Forward P/E |
83.3x
|
21.0x
|
| EV / EBITDA |
23.4x
|
7.5x
|
| Price / Sales |
5.7x
|
2.6x
|
| Price / FCF |
18.7x
|
8.4x
|
| Revenue Growth YoY |
+10.0%
|
-2.5%
|
| Gross Margin |
70.2%
|
33.1%
|
| Operating Margin |
26.7%
|
25.4%
|
| Return on Equity |
-361.6%
|
11.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
11.96%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
ConocoPhillips is a leading independent oil and gas exploration and production company with a strong focus on low-cost shale assets and sustainability initiatives. The company benefits from a durable competitive position due to its cost advantage and early ESG leadership, but faces near-term earnings pressure as revenue declined 2.5% and earnings fell 23.4% in the most recent quarter year-over-ye…
Accumulation Zones
| Metric |
ABBV |
COP |
| Zone Low |
$157.66 |
$92.36 |
| Zone High |
$178.69 |
$104.68 |
| In Buy Zone? |
No
|
No
|